Initiate Insulin by Aggressive Titration and Education (INITIATE)
The DOI matches its Crossref record, with a small difference in title or year; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective Insulin is often postponed for years because initiation is time-consuming. We sought to compare initiation of insulin individually and in groups with respect to change in A1C and several other parameters in type 2 diabetic patients. Research design and methods A randomized (1:1), multicenter, two-arm, parallel design study with a recruiting period of up to 14 weeks and a 24-week treatment period. Either in groups of 4-8 or individually, using the same personnel and education program, 121 insulin-naive type 2 diabetic patients with an A1C of 7.0-12.0% were randomized to initiate bedtime insulin glargine. The patients visited the treatment center before and at the time of insulin initiation and at 6, 12, and 24 weeks. Patients self-adjusted the insulin dose to achieve a fasting plasma glucose 4.0-5.5 mmol/l. Results At 24 weeks, mean +/- SE A1C had decreased from 8.7 +/- 0.2 to 6.9 +/- 0.1% in those treated individually and from 8.8 +/- 0.2 to 6.8 +/- 0.1% in those in groups (not significant [NS]). Insulin doses averaged 62 +/- 5 IU and 56 +/- 5 IU at 24 weeks (NS), respectively. The frequency of hypoglycemia was similar. The total time (visits and phone calls) spent in initiating insulin in the patients in groups (2.2 +/- 0.1 h) was 48% less than in those treated individually (4.2 +/- 0.2 h). Diabetes treatment satisfaction improved significantly in both sets of patients. Conclusions Similar glycemic control and treatment satisfaction can be achieved by initiating in…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, several insulin treat-to-target trials have safely used dose titration protocols in individuals not at target A1C to reach lower than”
From Targets for Glycemic Control (2018) · cites this paper as [43]
In the citing paper
“A study performed on insulin initiation, and titration suggested that individual treatment rather than group treatment effectively controlled body weight [27].”
Citations
Cites
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891 · cited 1×
“Randomization was performed centrally, using the minimization of differences method (11).”
MethodYki-Järvinen, H., Dressler, A., Ziemen, M., & HOE 901/300s Study Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1130 · Cited by 579
Initiating Insulin Therapy in Type 2 Diabetes
Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., Garber, A., & for the INITIATE Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.2.260 · Cited by 560
Wright, A., Burden, A. C. F., Paisey, R. B., Cull, C. A., Holman, R. R., & for the U.K. Prospective Diabetes Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.2.330 · Cited by 556
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Self-citationYki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
Self-citationJanka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Patient perceptions of diabetes and diabetes therapy: assessing quality of life
Bradley, C., & Speight, J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.279 · Cited by 362
Fritsche, A., Schweitzer, M. A., Hring, H.-U., & and the 4001 Study Group* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00006 · Cited by 331
Cited by
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.3.154 · Cited by 286
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240
“6 mmol/L) according to a prespecified treat-to-target algorithm (8).”
MethodDiamant, M., Nauck, M. A., Shaginian, R., Malone, J. K., Cleall, S., Reaney, M., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 228
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211
Diamant, M., van Gaal, L., Guerci, B., Stranks, S., Han, J., Malloy, J., Boardman, M. K., & Trautmann, M. (2014) · The Lancet Diabetes and Endocrinology · doi:10.1016/s2213-8587(14)70029-4 · Cited by 163
Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes
Yki-Järvinen, H., Rosenstock, J., Durán-Garcia, S., Pinnetti, S., Bhattacharya, S., Thiemann, S., Patel, S., & Woerle, H.-J. (2013) · Diabetes Care · doi:10.2337/dc12-2718 · Cited by 134
Diagnosing and managing diabetes in HIV-infected patients: current concepts
Monroe, A. K., Glesby, M. J., & Brown, T. T. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu779 · Cited by 125
Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes
Fu, A. Z., Qiu, Y., & Radican, L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902905724 · Cited by 124
Imran, S. A., Agarwal, G., Bajaj, H. S., & Ross, S. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.030 · Cited by 113
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Drent, M. L., Diamant, M., & IJzerman, R. G. (2016) · Diabetes Care · doi:10.2337/dc15-0772 · Cited by 102
Diamant, M., Van Gaal, L., Stranks, S., Guerci, B., MacConell, L., Haber, H., Scism-Bacon, J., & Trautmann, M. (2012) · Diabetes Care · doi:10.2337/dc11-1233 · Cited by 96
“INITIATE trial (5), and the continuation of patients in their originally assigned randomization arm, eliminating the possibility of any carryover effects from changing therapies.”
BackgroundResultNayak, A., Vakili, S., Nayak, K., Nikolov, M., Chiu, M., Sosseinheimer, P., Talamantes, S., Testa, S., Palanisamy, S., Giri, V., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.40232 · Cited by 82
Guja, C., Frías, J. P., Somogyi, A., Jabbour, S., Wang, H., Hardy, E., & Rosenstock, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13266 · Cited by 78
“5 mmol/L [72-99 mg/dL]).(28) Suboptimal titration was shown by smaller-than-expected increases in the IG dose, especially with placebo, despite elevated FPG levels.”
BackgroundFonseca, V. A., Gill, J., Zhou, R., & Leahy, J. L. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01412.x · Cited by 80
Davies, M. J., Lavalle-Gonzalez, F. J., Storms, F., Gomis, R., & AT.LANTUS Study Group (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00873.x · Cited by 72
Self-citationGoodall, G., Sarpong, E., Hayes, C., & Valentine, W. J. (2009) · BMC Endocrine Disorders · doi:10.1186/1472-6823-9-19 · Cited by 66
Strange, P. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100412 · Cited by 59
Juurinen, L., Kotronen, A., Granér, M., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1825 · Cited by 58
Self-citationCrasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2009) · Postgraduate Medical Journal · doi:10.1136/pgmj.2008.067926 · Cited by 57
Self-citationCommon Standards of Basal Insulin Titration in T2DM
Arnolds, S., Heise, T., Flacke, F., & Sieber, J. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700323 · Cited by 52
The Potential of Group Visits in Diabetes Care
Davis, A. M., Sawyer, D. R., & Vinci, L. M. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.2.58 · Cited by 51
Riddle, M. C., Vlajnic, A., Zhou, R., & Rosenstock, J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12096 · Cited by 56
Philis‐Tsimikas, A., Brod, M. I., Niemeyer, M., Francisco, A. M. O., & Rothman, J. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0036-1 · Cited by 48
Insulin Glargine: a review 8 years after its introduction
Goykhman, S., Drincic, A., Desmangles, J. C., & Rendell, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902775677 · Cited by 49
DAILEY, G. E., Admane, K., Mercier, F., & Owens, D. R. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0063 · Cited by 49
Davies, M. J., Russell-Jones, D. L., Selam, J. L., Bailey, T. S., Kerényi, Z., Luo, J., Bue‐Valleskey, J. M., Iványi, T., Hartman, M. L., Jacobson, J. G., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12712 · Cited by 48
Self-citationHow much is too much? Outcomes in patients using high‐dose insulin glargine
Reid, T., Gao, L., Gill, J., Stuhr, A., Traylor, L. B., Vlajnic, A., & Rhinehart, A. S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12747 · Cited by 48
Khunti, K., Davies, M. J., & Kalra, S. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12053 · Cited by 45
Self-citationBradley, C., & Gilbride, C. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00871.x · Cited by 45
Owens, D. R., Traylor, L., Dain, M., & Landgraf, W. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.08.003 · Cited by 44
Edelman, S. V., Liu, R., Johnson, J. L., & Glass, L. C. (2014) · Diabetes Care · doi:10.2337/dc13-2664 · Cited by 44
LaSalle, J. R., & Berria, R. (2013) · PubMed · Cited by 42
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Woehl, A., Evans, M., Tetlow, A., & McEwan, P. (2008) · Cardiovascular Diabetology · doi:10.1186/1475-2840-7-24 · Cited by 41
Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers
Kuritzky, L., Reid, T., & Wysham, C. (2019) · Clinical Diabetes · doi:10.2337/cd18-0091 · Cited by 40
Giugliano, D., Maiorino, M., Bellastella, G., Chiodini, P., & Esposito, K. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02619.x · Cited by 36
Is insulin the most effective injectable antihyperglycaemic therapy?
Buse, J. B., Peters, A., Russell‐Jones, D., Furber, S., Donsmark, M., Han, J., MacConell, L., Maggs, D., & Diamant, M. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12402 · Cited by 32
van Ruiten, C. C., ten Kulve, J. S., van Bloemendaal, L., Nieuwdorp, M., Veltman, D. J., & IJzerman, R. G. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105667 · Cited by 31
“The daily dose was increased based on fasting self-monitored blood glucose levels according to a predetermined treat-to-target algorithm (Yki-Jarvinen et al., 2007).”
Wang, Y., Li, L., Yang, M., Liu, H., Boden, G., & Yang, G. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01436.x · Cited by 30
Effect of Technosphere Inhaled Insulin on Quality of Life and Treatment Satisfaction
Peyrot, M. F., & Rubin, R. R. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0115 · Cited by 29
Initiating insulin in patients with type 2 diabetes
Lau, A. N. C., Tang, T., Halapy, H., Thorpe, K. E., & Yu, C. H. Y. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.110779 · Cited by 32
van Raalte, D. H., Bunck, M. C. M., Smits, M. M., Hoekstra, T., Cornér, A., Diamant, M., Eliasson, B., Marja-RiittaTaskinen, Heine, R. J., Smith, U., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0286 · Cited by 31
Blonde, L., Brunton, S., Chava, P., Zhou, R., Meyers, J., Davis, K. L., Dalal, M. R., & DIGENIO, A. G. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0082 · Cited by 33
Chen, W. J. Y., Diamant, M., de Boer, K., Harms, H. J., Robbers, L. F. H. J., van Rossum, A. C., Kramer, M. H. H., Lammertsma, A. A., & Knaapen, P. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0549-z · Cited by 27
Peyrot, M. F., & Rubin, R. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0037 · Cited by 26
Pharmacologic Treatment of Type 2 Diabetes: Injectable Medications
Tran, L., Zielinski, A., Roach, A. H., Jende, J. A., Householder, A. M., Cole, E. E., Atway, S. A., Amornyard, M., Accursi, M. L., Shieh, S. W., et al. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573010 · Cited by 32
Odawara, M., Ohtani, T., & Kadowaki, T. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0220 · Cited by 26
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Karl, D. M., Gill, J., Zhou, R., & Riddle, M. C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12072 · Cited by 21
Dalal, M. R., Xie, L., Başer, O., & DIGENIO, A. G. (2014) · Endocrine Practice · doi:10.4158/ep14290.or · Cited by 19
Jones, H., Berard, L., Macneill, G., Whitham, D., & Yu, C. H. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.015 · Cited by 37
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Castellana, M., Procino, F., Sardone, R., Trimboli, P., & Giannelli, G. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001477 · Cited by 19
Lin, S.-D., Tsai, S., Tu, S., Su, C., Chen, J., Lu, C., Wang, C., Yu, N.-C., Hsu, S.-R., & Hsieh, M. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2014.05.005 · Cited by 15
The importance of titrating starting insulin regimens in patients with type 2 diabetes
Garber, A. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01138.x · Cited by 15
Rosenstock, J., Eliaschewitz, F. G., Heilmann, C. R., Muchmore, D. B., Hayes, R. P., & Belin, R. M. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0059 · Cited by 15
Upsher, R. J., Allen-Taylor, M., Reece, I., Chamley, M., Ismail, K., Forbes, A., & Winkley, K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00727-7 · Cited by 14
“Diabetes group education is cost-effective compared with individual support [11].”
BackgroundLong-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden
Smith‐Palmer, J., Fajardo, C., Pollock, R. F., Ericsson, Å., & Valentine, W. J. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.692340 · Cited by 14
Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes
Juurinen, L., Tiikkainen, M., Saltevo, J. T., Nikkilä, K., Lanki, H., Leppävuori, E., Kock, T., Teikari‐Myyrä, T., Kauppinen‐Mäkelin, R., Kotronen, A., et al. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02691.x · Cited by 14
Self-citationGallwitz, B., & Bretzel, R. G. (2013) · Diabetes Care · doi:10.2337/dcs13-2012 · Cited by 16
Sharma, S. K., Thakur, K., Kant, R., & Mudgal, S. K. (2021) · Cureus · doi:10.7759/cureus.20436 · Cited by 13
“A study performed on insulin initiation, and titration suggested that individual treatment rather than group treatment effectively controlled body weight [27].”
BackgroundMethodThe effect of an mHealth intervention for titration of insulin for type 2 diabetes: A pilot study
Bramwell, S., Meyerowitz‐Katz, G., Ferguson, C., Jayaballa, R., McLean, M. P., & MABERLY, G. F. (2019) · European Journal of Cardiovascular Nursing · doi:10.1177/1474515119889764 · Cited by 16
Vilsbøll, T., Ekholm, E., JOHNSSON, E. K., García‐Sánchez, R., Dronamraju, N., Jabbour, S. A., & Lind, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13981 · Cited by 12
DAILEY, G. E., Aurand, L. A., Stewart, J. A., Ameer, B., & Zhou, R. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12080 · Cited by 13
Jain, S. M., Seshadri, K., Unnikrishnan, A. G., Chawla, M. S., Kalra, P., Vipin, V. P., Ravishankar, E., Chordia, J., Das, S., Wasir, J. S., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00770-9 · Cited by 13
LEVIN, P. A. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00845.x · Cited by 12
Nurse-led diabetes clinics in Southeast Asia: scope, feasibility, challenges and facilitators
K Sharma, S., Thakur, K., Kant, R., & Kalra, S. (2020) · Journal of Diabetes, Metabolic Disorders & Control · doi:10.15406/jdmdc.2020.07.00199 · Cited by 8
Practical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus
Chan, S. P., Aamir, A. H., Bee, Y. M., Deerochanawong, C., Paz-Pacheco, E. T., Tiu, F., Foo, S. H., Tan, K. E. K., Le, T. Q., Saraswati, M. R., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01286-0 · Cited by 14
Chen, S., Lu, J., Peng, D., Liu, F., Lu, W., Zhu, W., Zhou, J., & Jia, W. (2022) · Diabetes Care · doi:10.2337/dc22-0510 · Cited by 13
Kim, J., Ahn, J., Kim, S., Lee, D., Kim, H., Shon, H., Jeon, H.-J., Kim, T., Cho, Y., Kim, J., et al. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12261 · Cited by 12
Lee, L. J., Fahrbach, J. L., Nelson, L. M., McLeod, L., Martin, S., Sun, P., & Weinstock, R. S. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.04.002 · Cited by 12
Hanefeld, M., Traylor, L., Gao, L., & Landgraf, W. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0548-0 · Cited by 11
“4041 [45] 4 Gla-100 with group education + OADs vs.”
BackgroundShi, C., Zhang, R., Bai, R., Liu, D., Wang, Y., Zhang, X., Wang, H., & Du, J. (2019) · Clinics · doi:10.6061/clinics/2019/e736 · Cited by 11
“For patients who had FBGo5 mmol/L or showed hypoglycemia without obvious cause, the insulin glargine dose was decreased by 2 U, as described previously (14).”
MethodRiddle, M. C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2576 · Cited by 11
Deerochanawong, C., Bajpai, S., Dwipayana, I. M. P., Hussein, Z. B., Mabunay, M. A., Rosales, R., Tsai, S., & Tsang, M. W. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0322-z · Cited by 11
Misra, A., Patel, M., Agarwal, P., Lodha, S., Tandon, N., Magdum, M., Yajnik, C. S., GHOSH, R., & Walekar, A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0037 · Cited by 13
Li, X., Du, T., Li, W., Zhang, T., Liu, H., & Xiong, Y. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.032 · Cited by 10
Owens, D. R., Bolli, G. B., Charbonnel, B. H., Haak, T., Landgraf, W., Porcellati, F., Traylor, L., & Kautzky‐Willer, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12966 · Cited by 11
King, A. B., & Clark, D. (2014) · Endocrine Practice · doi:10.4158/ep14334.or · Cited by 9
Leahy, J. L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79214-x · Cited by 9
Polonsky, W. H., Traylor, L. B., Wei, W., Shi, R., Ameer, B., Vlajnic, A., & Nicolucci, A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12214 · Cited by 10
Pscherer, S., Anderten, H., Pfohl, M., Fritsche, A., Borck, A., Pegelow, K., Bramlage, P., & Seufert, J. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01383-w · Cited by 8
Riebenfeld, D., Spirk, D., Mathis, A., Villiger, L., Gerber, P. A., Gasser, U., & Lehmann, R. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14114 · Cited by 7
Kanatsuka, A., Sato, Y., Kawai, K., Hirao, K., Kobayashi, M., & Kashiwagi, A. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12194 · Cited by 7
Gu, T., Hong, T., Zhang, P., Tang, S., Bi, Y., Lu, H., Men, L., Ma, D., & Zhu, D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0381-9 · Cited by 8
Tian, Q., Upsher, R. J., & Winkley, K. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2021.06.030 · Cited by 6
Insulin glargine and its role in glycaemic management of Type 2 diabetes
Elrishi, M., Jarvis, J., Khunti, K., & Davies, M. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.8.1099 · Cited by 7
Self-citationImplementación de la estrategia basal plus en la práctica clínica
Alfaro, A. Á. M., Soidán, F. J. G., Guisasola, F. Á., Jl, B. L., Laureano, F. C. S., Zornoza, P. C., Viñau, F. L., Marco, A., Pérez-Lázaro, A., Pérez-Maraver, M., et al. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)65007-7 · Cited by 8
Mathieu, C., & Robbrecht, S. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00841.x · Cited by 8
Insulin Therapy in Type 2 Diabetes
Wyne, K. L., & Mora, P. F. (2007) · Endocrine Research · doi:10.1080/07435800701743836 · Cited by 6
Individual and Group Education in Diabetes and Outcomes
Ünsal-Avdal, E., & Arkan, B. (2014) · Aquichan · doi:10.5294/aqui.2014.14.2.1 · Cited by 7
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes
Hao, S., Umpierrez, G. E., & Vellanki, P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.004 · Cited by 6
Karl, D. M., Zhou, R., Vlajnic, A., & Riddle, M. C. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03640.x · Cited by 7
Metadata
- Authors
- Yki-Järvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenperä, S., Nijpels, G., & Vähätalo, M.
- Affiliations
- University of Helsinki, Helsinki, Finland
- University of Helsinki (FI)
- Karolinska University Hospital (SE)
- Bolton NHS Foundation Trust (GB)
- Leicester Royal Infirmary (GB)
- Sanofi-Aventis, Helsinki, Finland
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Turku Health Center, Turku, Finland
- ORCID
- Davies, Melanie
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 30
- Issue
- 6
- Pages
- 1364-1369
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2163457223
- Cited by
- 139
- References
- 13
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 5 · 2014: 16 · 2013: 17 · 2012: 11
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- insulin initiation, type 2 diabetes, insulin glargine, bedtime insulin, patient education, insulin dose adjustment, glycemic control, HbA1c, hypoglycemia, treatment satisfaction
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Patient Education as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.